FDA Approves Nemolizumab for PN: Here’s What to Know
The U.S. Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. Nemolizumab specifically inhibits IL-31 cytokine signaling, which is known to drive itch and is involved in inflammation, altered epidermal differentiation, and fibrosis (hardening of skin tissue) in prurigo […]